metformin and glimepiride

metformin has been researched along with glimepiride in 249 studies

Research

Studies (249)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (0.80)18.2507
2000's60 (24.10)29.6817
2010's152 (61.04)24.3611
2020's35 (14.06)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Washburn, WN1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Ekins, S; Williams, AJ; Xu, JJ1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, C; Liu, J; Tang, J; Wu, F1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Lardinois, CK1
Bethel, MA; Feinglos, MN; Rao, SV1
Felgenhauer, N; Kochs, E; Reeker, W; Schneider, G; Tempel, G1
Riddle, M1
Brunelli, C; Cordera, R; Cordone, S; Olivotti, L; Rossettin, P; Schiavo, M; Spallarossa, P1
Charpentier, G; Fleury, F; Halimi, S; Kabir, M; Vaur, L1
Abbink, EJ; Jansen van Rosendaal, A; Lutterman, JA; Pickkers, P; Russel, FG; Smits, P; Tack, CJ1
Kiayias, JA; Lakka-Papadodima, E; Theodosopoulou, E; Vlachou, ED1
Davis, KR; Dhindsa, P; Donnelly, R1
Buković, D; Capkun, V; Gabrić, N; Karelović, D; Kokić, S; Lesko, V; Radman, M; Stancerić, T1
de Boer, H; Jansen, M; Koerts, J; Verschoor, L1
Abe, Y; Matsumoto, K; Miyake, S; Sera, Y; Tominaga, T; Yeki, Y1
Ciccarelli, L; Derosa, G; Fogari, R; Franzetti, I; Gadaleta, G1
Bayramiçli, OU; Gözü, H; Orbay, E; Sargin, H; Sargin, M; Yayla, A1
Ramachandran, A; Salini, J; Snehalatha, C; Vijay, V1
Janka, HU; Kliebe-Frisch, C; Plewe, G; Riddle, MC; Schweitzer, MA; Yki-Järvinen, H1
Komiya, I; Kouki, T; Nakachi, A; Takasu, N; Tamanaha, T; Tawata, M1
Kawamori, R1
Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Gaddi, AV; Ghelfi, M; Peros, E; Piccinni, MN; Salvadeo, S1
Ichiyanagi, K; Igarashi, K; Kawasaki, T; Sakai, T; Watanabe, H; Yamanouchi, T1
Feng, Q; Mao, JP; Tang, JZ; Tang, WL; Yang, ZF; Zhou, ZG1
Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Fogari, E; Fogari, R; Gaddi, AV; Ghelfi, M; Piccinni, MN; Pricolo, F; Salvadeo, S1
Bagool, MA; Deo, AA; Kolte, BL; Raut, BB; Shinde, DB1
Issa, M; Lake, B; Melis, R; Roberts, VL; Stewart, J1
Chopra, D; Kinagi, SB; Langade, DG; Meshram, DM; Morye, V; Naikwadi, AA1
Kabadi, M; Kabadi, UM1
Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Fogari, E; Gaddi, AV; Ghelfi, M; Piccinni, MN; Salvadeo, S1
Issa, M; Umpierrez, G; Vlajnic, A1
de Boer, H; Jansen, M; Keizers, R; Ruineman-Koerts, J; Verschoor, L1
Kann, PH; Medding, J; Moeller, J; Mokan, M; Mrevlje, F; Regulski, M; Szocs, A; Wascher, T; Zackova, V1
Ahn, CW; Cha, BS; Chung, CH; Kang, ES; Kim, DJ; Kim, HJ; Kim, SH; Lee, HC; Lee, KW; Nam, CM; Nam, M1
Busch, K; Janka, HU; Plewe, G1
Cara, JF; Danne, T; Gottschalk, M; Vlajnic, A1
Högy, B; Janka, HU1
Fanurik, D; Hermansen, K; Khatami, H; Kipnes, M; Luo, E; Stein, P1
Müller, UA; Schiel, R2
Hessel, F; Janka, HU; Mã Ller, E; Walzer, S1
Chou, HS; Hamann, A; Matthaei, S; Rosenstock, J; Seidel, DK1
Krishnarajah, G; Lyu, R; Mavros, P; Vexiau, P; Yin, D1
Amin, M; Jain, D; Jain, S1
Arulmozhi, DK; Bodhankar, SL; Kurian, R; Veeranjaneyulu, A1
Fiedorek, FT; Ledeine, JM; Rubin, CJ1
Düring, M; Frid, A; Hermansen, K; Matthews, DR; Mitha, IH; Nauck, M; Shah, NS; Tankova, T; Zdravkovic, M1
Diamant, M; Scheffer, PG; Schumm-Draeger, PM; Siegmund, T; von Bibra, H1
Abraira, C; Davis, SN; Duckworth, W; Emanuele, N; Goldman, S; Hayward, R; Henderson, WG; Huang, GD; Marks, J; McCarren, M; Moritz, T; Reaven, PD; Reda, D; Vitek, ME; Warren, SR; Zieve, FJ1
Ahrén, B; Byiers, S; Dejager, S; Ferrannini, E; Fonseca, V; Matthews, D; Shao, Q; Zinman, B1
Kanioglou, C; Katsouras, CS; Kazakos, N; Kolettis, T; Liveris, K; Makriyiannis, D; Michalis, LK; Naka, KK; Papathanassiou, K; Pappas, K; Tsatsoulis, A1
Basha, S; Jain, R; Ramachandran, A; Shetty, S; Tripathy, NR1
Bax, JJ; de Jong, HW; de Roos, A; Diamant, M; Heine, RJ; Kamp, O; Lamb, HJ; Lammertsma, AA; Lubberink, M; Paulus, WJ; Rijzewijk, LJ; Romijn, JA; Smit, JW; van der Meer, RW1
Gropler, RJ1
Barnett, AH1
Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Salvadeo, SA1
Danne, T; Fuerst-Recktenwald, S; Gottschalk, M1
Antic, S; Dimic, D; Radenkovic, S; Velojic Golubovic, M1
Gallwitz, B; Guzmán, JR; Kazda, C; Kraus, P; Nicolay, C; Rose, L; Schernthaner, G; Simó, R1
Sharma, AK; Srinivasan, BP1
Ahrén, B; Dejager, S; Ferrannini, E; Foley, JE; Fonseca, VA; Matthews, DR; Zinman, B1
Cho, JY; Jang, IJ; Kim, BH; Kim, J; Kim, JR; Kim, KP; Lim, KS; Shin, KH; Shin, SG; Yu, KS1
de Haan, W; de Roos, A; Diamant, M; Jonker, JT; Lamb, HJ; Rensen, PC; Rijzewijk, LJ; Romijn, JA; Smit, JW; Tamsma, JT; van der Meer, RW; Wang, Y1
Hammer, M; Hermansen, K; Kolotkin, RL; Matthews, D; Zdravkovic, M1
Forst, T; Friedrich, C; Fuchs, W; Hohberg, C; Lehmann, U; Löbig, M; Müller, J; Pfützner, A; Weber, MM1
Minshall, ME; Sauriol, L; Tunis, SL1
Ahren, B; Couturier, A; Dejager, S; Ferrannini, E; Foley, JE; Fonseca, V; Matthews, DR; Zinman, B1
Cho, JY; Chung, JY; Gu, N; Jang, IJ; Kim, BH; Kim, JR; Rhim, H; Shin, HS; Shin, SG; Yoon, SH; Yu, KS1
Al-Jebawi, AF1
Boulton, DW; Griffen, SC; Kasichayanula, S; LaCreta, FP; Li, T; Liu, X; Pfister, M; Shyu, WC; Zhang, W1
Bech, OM; Bhattacharyya, A; Chen, L; Ji, Q; Kim, KW; Kumar, A; Liu, X; Ma, J; Tandon, N; Yang, W; Yoon, KH; Zychma, M1
Conner, C; Hammer, M; Lee, WC1
Arechavaleta, R; Chen, Y; Duran, L; Goldstein, BJ; Kaufman, KD; Krobot, KJ; O'Neill, EA; Seck, T; Williams-Herman, D1
Borkar, MS; Chandurkar, NB; Pareek, A; Salkar, HR; Tiwari, D1
Freeman, JS1
FU, XJ; GAO, F; HAN, YJ; HE, FY; WANG, M; XUE, YM1
Forst, T; Fuchs, W; Lehmann, U; Lobmann, R; Merke, J; Müller, J; Pfützner, A; Schöndorf, T; Tschöpe, D1
Bell, DS; Dharmalingam, M; Kumar, S; Sawakhande, RB1
Forst, T; Fuchs, W; Hohberg, C; Lehmann, U; Löbig, M; Müller, J; Musholt, PB; Pfützner, A; Schöndorf, T1
Bonaventura, A; Bossi, AC; Derosa, G; Fogari, E; Franzetti, IG; Guazzini, B; Maffioli, P; Putignano, P; Querci, F; Testori, G1
Choi, JH; Hwang, IK; Kim, W; Lee, CH; Nam, SM; Won, MH; Yoo, DY; Yoo, KY; Yoon, YS1
Chen, YM; Lu, HY; Mu, PW; Shu, J; Wang, MM; Wen, XQ; Xie, RY; Zeng, LY; Zhang, YH1
Cho, JY; Jang, IJ; Kim, SE; Shin, KH; Shin, SG; Yoon, SH; Yu, KS1
Bechlioulis, A; Kanioglou, C; Kazakos, N; Kostoula, A; Makriyiannis, D; Michalis, LK; Naka, KK; Papathanassiou, K; Pappas, K; Tsatsoulis, A; Vezyraki, P1
Jermendy, G1
Itoh, A; Itoh, H; Kawai, T; Meguro, S; Soeda, Y; Yoshino, T1
Arrigain, S; Atreja, A; Jain, A; Kattan, MW; Nutter, B; Pantalone, KM; Wells, BJ; Yu, C; Zimmerman, RS1
Cho, JY; Jang, IJ; Kim, BH; Kim, KP; Lim, KS; Shin, HS; Shin, SG; Yu, KS1
Kim, DW; Kim, JY; Kuk, YM; Oh, TO; Park, CW; Park, ES; Rhee, YS; Weon, KY1
Nauck, MA1
Arrigain, S; Atreja, A; Jain, A; Kattan, MW; Pantalone, KM; Wells, BJ; Yu, C; Zimmerman, RS1
Ong, CT; Sung, SF; Tong, SH; Wu, CS1
Basson, BR; Dotta, F; Festa, A; Gallwitz, B; Guerci, B; Guzman, J; Kiljański, J; Sapin, H; Schernthaner, G; Simó, R; Trautmann, M1
Hu, M; Sun, Z; Zeng, F; Zhou, Z1
Carallo, C; De Luca, S; Gnasso, A; Irace, C; Loprete, A; Scavelli, F; Shehaj, E1
Paquot, N; Scheen, AJ1
Bhattacharya, S; Dugi, KA; Gallwitz, B; Patel, S; Rauch, T; Rosenstock, J; von Eynatten, M; Woerle, HJ1
Colette, C; Comenducci, A; Dejager, S; Monnier, L; Vallée, D1
Gupta, R; Keshwani, P; Saxena, GN; Srivastava, S1
Bhansali, A; Sachdeva, N; Sridhar, S; Walia, R1
Bader, G; Dworak, M; Giani, G; Gruenberger, JB; Kostev, K; Rathmann, W1
Correia, MR; Cunha, MR; Fukui, RT; Lage, SG; Machado, HA; Rocha, DM; Santos, RF; Silva, ME; Vieira, M; Wajchenberg, BL1
Christensen, M; Knop, FK1
Flaherty, AM1
Barnett, AH; Harper, R; Patel, S; Thiemann, S; Toorawa, R; von Eynatten, M; Woerle, HJ1
During, M; Frid, A; Hermansen, K; Matthews, DR; Mitha, I; Nauck, M; Shah, N; Tankova, T; Thomsen, AB1
Gao, L; Li, SC; Zhao, FL1
Ben Said, R; Ben Salem, L; Ben Slama, C; Haouat, E; Kammoun, I; Oueslati, I; Turki, Z1
Ahn, CW; Baik, SH; Chung, DJ; Hwang, YC; Jang, HC; Kang, M; Kim, KA; Lee, IK; Lee, MK; Min, KW; Nam, M; Park, JS; Park, KS; Park, TS; Son, SM; Sung, YA; Woo, JT1
Berndt-Zipfel, C; Dworak, M; Forst, T; Klamp, I; Löffler, A; Mitry, M; Pfützner, A1
Arai, K; Hirao, K; Hirao, S; Hirao, T; Maeda, H; Sirabe, S; Yamamoto, R; Yamauchi, M1
Del Prato, S; Nauck, M1
Bader, G; Geransar, P; Schweizer, A1
Berndt-Zipfel, C; Dworak, M; Forst, T; Löffler, A; Michelson, G; Mitry, M; Pfützner, A1
Charbonnel, B; Davies, MJ; Engel, SS; Eymard, E; Prabhu, V; Steinberg, H; Thakkar, P; Xu, L1
Buse, JB; Kahn, SE; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Staten, M; Wexler, D1
Bruce, SS; Connolly, ES; Heyer, EJ; Mergeche, JL1
Forst, T; Foteinos, G; He, YL; Kulmatycki, K; Mattapalli, D; Neelakantham, S; Taylor, A1
Arayne, MS; Sultana, N; Tabassum, A1
Arias, P; Balis, DA; Canovatchel, W; Cefalu, WT; Leiter, LA; Meininger, G; Niskanen, L; Xie, J; Yoon, KH1
Chang, MP; Chen, CC; Hung, YC; Lin, CC; Sung, FC; Wang, TY1
Broedl, UC; Kim, G; Ridderstråle, M; Svaerd, R; Woerle, HJ; Zeller, C1
Anastassiadis, E; Diessel, S; Forst, T; Löffler, A; Pfützner, A1
Mezquita Raya, P; Reyes García, R1
Seufert, J1
Adamson, U; Landstedt-Hallin, L; Lins, PE; Nybäck-Nakell, Å1
Arai, K; Hirao, K; Hirao, S; Hirao, T; Kumakura, A; Maeda, H; Shirabe, S; Yamamoto, R; Yamauchi, M1
Chon, S; Kang, JG; Lee, CB; Noh, J; Oh, SJ; Park, CY; Park, SW1
Agrawal, N; Bhandari, S; Chandurkar, N; Deshpande, A; Devaramani, S; Gupta, OP; Kakrani, A; Kothari, K; Mahesh, M; Pareek, A; Saboo, B; Shah, A; Sharma, S; Thomas, N; Thulasidharan, NK; Vijaykumar, NB; Viswanathan, V1
Antonioli, R; Bogo, MR; Bonan, CD; Capiotti, KM; Da Silva, RS; Kist, LW1
Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D2
Ahrén, B; Cirkel, DT; Feinglos, MN; Johnson, SL; Perry, C; Stewart, M; Yang, F1
Andersen, KR; Broedl, UC; Kim, G; Ridderstråle, M; Woerle, HJ; Zeller, C1
Persson, U; Steen Carlsson, K1
Bolli, GB; Candelas, C; Dain, MP; Deerochanawong, C; Home, PD; Landgraf, W; Mathieu, C; Pilorget, V; Riddle, MC1
Arias, P; Balis, DA; Canovatchel, W; Langslet, G; Leiter, LA; Meininger, G; Millington, D; Vercruysse, F; Xie, J; Yoon, KH1
Ahmed, R1
Carr, MC; Home, PD; Miller, M; Perry, C; Shamanna, P; Stewart, M; Yang, F1
Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A1
Chai, Z; Li, L; Liu, C; Shen, X; Wang, L; Zhang, X; Zhang, Z1
Almendro, N; Amate, JM; Bouza, C; Gonzalez-Canudas, J; Lopez-Cuadrado, T; Rivas-Ruiz, R; Saz-Parkinson, Z1
Durán-Garcia, S; Hanefeld, M; Hardy, E; Langslet, G; Malvolti, E; Niskanen, L; Östgren, CJ; Schernthaner, G1
Nagai, Y1
Brunetti, A; Capula, C; Chiefari, E; Foti, D; Greco, M; Liguori, R; Oliverio, R; Puccio, L; Pullano, V; Tirinato, D; Vero, A; Vero, R1
Dotta, F; Festa, A; Gallwitz, B; Guerci, B; Kiljański, J; Rosas-Guzmán, J; Schernthaner, G; Simó, R; Zhou, M2
Aggarwal, N; Amin, NB; Calle, RA; Denney, WS; Le, V; Pall, D; Paragh, G; Riggs, M1
Deng, J; Dong, H; Gu, S; Mu, Y; Shi, L1
Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y; Ubukata, M1
Ahmed, SA; Mohamed, AM; Mohamed, FA; Mohamed, YA1
Beckers, J; Hansen, JS; Häring, HU; Hoene, M; Hrabĕ de Angelis, M; Irmler, M; Lehmann, R; Li, Y; Liu, X; Pedersen, BK; Plomgaard, P; Scheler, M; Weigert, C; Xu, G; Zhao, X1
Benroubi, M; Giorgino, F; Pechtner, V; Sun, JH; Zimmermann, AG1
Aruljothi, KN; Dannie, MA; Devi, A; Harishankar, MK; Logeshwaran, S; Sujeevan, S1
Fukase, H; Harigai, M; Iida, S; Ikeda, S; Kasahara, N; Miyata, K; Ohba, Y; Saito, T; Takano, Y; Terao, K1
Abd-Allah, GM; Hassan, MH1
Chirila, C; Davenport, E; Hach, T; Kaschinski, D; Palencia, R; Pfarr, E; Zheng, Q1
Ambery, P; Atkinson, G; Baylor Curtis, L; Dott, C; Haque, N; LaCroix, K; Min, KW; Stylianou, A1
Alba, M; Cerdas, S; Chacon, Mdel P; Eliaschewitz, FG; Lavalle-González, FJ; Tong, C1
Gilowski, W; Krysiak, R; Okopień, B1
Belardinelli, L; Dhalla, A; Eckel, RH; Guan, S; Henry, RH; Jochelson, P; McNabb, B; Pettus, J; Skyler, JS1
Geissel, W1
Blonde, L; Canovatchel, W; Fung, A; Meininger, G; Stenlöf, K; Xie, J1
Ako, J; Anzai, T; Eguchi, K; Inoue, T; Kitakaze, M; Murohara, T; Node, K; Oyama, J; Saito, Y; Sakata, Y; Sata, M; Sato, Y; Shimizu, W; Suzuki, M; Taguchi, I; Tanaka, A; Tomiyama, H; Ueda, S; Uematsu, M; Watada, H; Yamashina, A1
El-Zaher, AA; Elkady, EF; Elwy, HM; Saleh, MA1
Chung, SC; Kim, IJ; Kim, SS; Kim, YI; Lee, KJ; Lee, SJ; Lee, YS; Park, JH1
Bailey, RA; Blonde, L; Meininger, G; Patel, CA; Vijapurkar, U1
Alam, F; Gan, SH; Islam, MA; Kamal, MA1
Ali, Z; Daniyal, M; Naveed, S; S I, I; Usmanghani, K1
Bilo, H; Bouma, A; Groenier, KH; Kleefstra, N; Landman, GW; van Dijk, P; van Hateren, KJ1
Amin, S; Farooq, R; Hayat Bhat, M; Majid, S; Malik, R; Wani, HA1
Aoki, S; Atsumi, T; Furumoto, T; Inoue, A; Kurihara, Y; Manda, N; Miyoshi, H; Nomoto, H; Oba, K; Tsutsui, H1
Hemmingsen, B; Metzendorf, MI; Richter, B; Sonne, DP1
Chen, YT; Dong, Y; Li, CY; Shou, D; Yang, YX1
Cook, W; Hirshberg, B; Ohman, P; Perl, S; Wei, C1
Cho, JH; Hur, GC; Jang, YH; Jung, CH; Kim, JH; Kim, SH; Lee, BW; Lee, SH; Lee, WJ; Park, CY; Park, SE; Suh, S1
Berk, A; Chilton, R; Esmaeili, H; Jax, T; Marx, N; Stirban, A; Terjung, A; Thiemann, S; von Eynatten, M1
Bi, Y; Engel, SS; Ji, L; Ji, Q; Jia, W; Lu, J; Mao, A; Mu, Y; Ran, X; Weng, J; Xu, W; Yang, W; Yao, B; Zeng, L; Zhao, B; Zhao, J; Zhou, Z; Zhu, D1
Nishimura, N; Shimada, Y; Zang, L1
Hur, KY; Jin, SM; Kim, G; Kim, JH; Lee, MK; Oh, S1
Gantz, I1
Katakami, N; Matsuoka, TA; Shimomura, I; Shiraiwa, T; Takahara, M1
Ceesay, P; Engel, SS; Gantz, I; Kaufman, KD; Lai, E; Latham, M; Lee, SH; O'Neill, EA; Round, E; Suryawanshi, S1
Ahn, KJ; Baik, SH; Chon, S; Kim, YS; Koh, G; Lee, DH; Lee, KW; Nam, MS; Park, Y; Rhee, SY; Woo, JT; Yoo, SJ1
Cuddihy, R; Davies, MJ; Garvey, WT; Leiter, LA; List, J; Ren, J; Van Gaal, L; Vijapurkar, U1
Baklavaridis, A; Bouropoulos, N; Fatouros, DG; Gioumouxouzis, CI; Katsamenis, OL; Markopoulou, CK; Tzetzis, D1
Ahn, KJ; Cha, BY; Chung, MY; Kang, JG; Kim, IJ; Kim, JD; Kim, JT; Lee, HW; Min, KW; Park, CY; Park, KS; Park, SW; Won, JC1
Liu, X; Xu, W; Zeng, L1
Hao, M; Kuang, HY; Li, BW; Ma, XF; Pan, J; Shao, N; Wu, WH; Yu, XY; Yu, YM; Zhang, HJ1
Alvey, C; Cutler, DL; Dawra, VK; Hickman, A; Krishna, R; Liang, Y; Sahasrabudhe, V; Saur, D; Shi, H; Terra, SG; Zhou, S1
Kaspers, S; Kohler, S; Salsali, A; Woerle, HJ; Zeller, C1
Csomós, K; Cypryk, K; Dronamraju, N; Garcia-Sanchez, R; Jacob, S; Johnsson, E; Kellerer, M; Kurlyandskaya, R; Müller-Wieland, D; Rohwedder, K; Seufert, J; Sjöström, CD; Skripova, D1
Andersen, KR; Ridderstråle, M; Rosenstock, J; Salsali, A; Woerle, HJ1
Chen, SH; Liu, XN; Peng, Y; Sun, QY1
Choi, KM; Jang, HC; Kang, ES; Kim, DJ; Kim, ES; Kim, NH; Kim, SJ; Kim, SR; Kim, Y; Lee, MK; Oh, T; You, J1
Bi, Y; Cheng, J; Gu, T; Li, D; Ma, J; Shao, J; Shi, B; Sun, Z; Xu, L; Zhang, H; Zhang, Q; Zhong, S; Zhu, D; Zhu, L1
Bello-López, MÁ; Butnaru, E; Caba, IC; Fernández-Torres, R; Kazakova, J; Strugaru, AM1
Charbonnel, B; Darekar, A; Gallo, S; Goldman, A; Huyck, S; Lauring, B; Shi, H; Terra, SG1
Abdel Salam, RA; Abdelhady, KK; El-Wekil, MM; Hadad, GM1
Frias, JP1
Digtiar, NI; Kaidashev, IP; Kaidasheva, EI; Savchenko, LG; Selikhova, LG; Shlykova, OA; Vesnina, LE1
Kaundal, PK; Mokta, JK; Mokta, K; Sahai, AK1
Chun, SW; Hong, JH; Kim, SJ; Lee, JM; Lim, DM; Park, KS; Park, KY; Yu, HM1
Bian, X; Cai, L; Gan, Z; Guan, X; Hu, X; Jiang, L; Zhang, L1
Banzal, S; Farishta, F; Godbole, SG; Modi, KD; Phatak, S1
Kashiv, P; Kumar, J1
Dronamraju, N; Frias, JP; Garcia-Sanchez, R; Gonzalez-Galvez, G; Johnsson, E; Maaske, J; Peters, AL; Simonson, DC; Testa, MA1
Ai, M; Anai, M; Fujishiro, M; Inazawa, T; Inoue, M; Ishihara, H; Kitazawa, T; Kuroda, H; Ohashi, H; Seino, H; Yamada, M1
Fan, H; Jin, P; Liu, Y; Mai, X; Pi, J; Xie, X; Yue, Z; Zhang, W; Zhang, Y1
Chakravarti, HN; Nag, A1
Ag, U; J, G; K, P; Mv, A; S, V1
Danser, AHJ; Hartmann, B; Holst, JJ; Joles, JA; Kramer, MHH; Muskiet, MHA; Ouwens, DM; Smits, MM; Tonneijck, L; Touw, DJ; van Raalte, DH1
Kabel, M; Mostafa, T; Omran, G; Shokry, A; Werida, R1
Hansen, HS; Jessen, JB; Johannsen, ML; Munkboel, CH; Styrishave, B1
Jasmine, MR; Nanda, N; Pal, GK; Sahoo, J; Velkumary, S1
Tack, CJ; van de Laar, FA1
Chiriac, FL; Iancu, VI; Radu, GL; Scutariu, RE1
Hsu, CC; Hwu, CM; Su, YC; Wei, JC; Yen, FS1
Amarin, JZ; Beirat, AF; Hasan, YY; Hassoun Al Najar, AM; Qtaishat, A; Tierney, ME; Zaghlol, LY; Zaghlol, RY; Zayed, AA1
Bilker, WB; Brensinger, CM; Flory, JH; Hee Nam, Y; Hennessy, S; Leonard, CE1
Frías, JP; Hockings, PD; Iqbal, N; Johansson, L; Maaske, J; Suchower, L; Wilding, JPH1
Chen, FW; Hou, KJ; Khan, BA; Wu, Z; Wu, ZZ; Zhang, S1
Hyötyläinen, T; Jendle, J; Nyström, T; Orešič, M1
Choi, SH; Chun, SW; Hur, KY; Jeong, IK; Kang, ES; Kim, HJ; Kim, SK; Noh, JH; Rhee, EJ1
Balasubramanyam, A; Burch, HB; Buse, JB; Butera, NM; Cohen, RM; Crandall, JP; Kahn, SE; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Rasouli, N; Tiktin, M; Wexler, DJ; Younes, N1
Bebu, I; Burch, HB; Buse, JB; Cherrington, AL; Fortmann, SP; Green, JB; Kahn, SE; Kirkman, MS; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Phillips, LS; Pop-Busui, R; Steffes, M; Tiktin, M; Tripputi, M; Wexler, DJ; Younes, N1
Crown, W; Deng, Y; Dhruva, SS; Gandotra, C; Herrin, J; Lyon, TD; McCoy, RG; Noseworthy, P; Polley, EC; Quinto, K; Ross, JS; Shah, ND; Wallach, JD; Yao, X1
Imai, K; Iwazaki, A1
Bhat, MH; Masoodi, SR; Mir, SA; Najar, IA; Patyar, RR; Patyar, S1
Cauchon, M; Lanthier, L; Mutchmore, A; Plourde, MÉ1
Brown, K; Donato, AA1
Ahn, J; Florez, JC; Lim, S; Nauck, MA; Sohn, M1
Kesavadev, J; Kumar Das, A; Maheshwari, A; Makkar, BM; Modi, KD; Mohan, V; Saboo, B; Shrestha, D; Shrivastava, A1
Gayakvad, B; Kothari, C; Patel, C; Patel, R; Solanki, R; Wadhwana, P1
Abbas, SQ; Ahmad, SA; Ahmed, S; Ahmed, Z; Akhter, E; Andleeb, S; Asif, M; Hussain, MW; Iqbal, A; Ishaqui, AA; Jawed, B1
Elkhodary, MM; Hammad, SF; Kamal, AH; Marie, AA; Salim, MM1
Abdullah, K; Alsadoon, L1
Chung, SM; Hong, JH; Hwang, IC; Lim, S; Moon, JS1
Bebu, I; de Boer, IH; Ghosh, A; Inzucchi, SE; Ismail-Beigi, F; McGill, JB; Mudaliar, S; Schade, D; Steffes, MW; Tamborlane, WV; Tan, MH; Wexler, DJ; Younes, N1
Andjelic-Jelic, M; Beljic-Zivkovic, T; Jojic, B; Marjanovic-Petkovic, M; Stojanovic, J; Stojanovic, M; Vuksanovic, M1

Reviews

23 review(s) available for metformin and glimepiride

ArticleYear
Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
    Journal of medicinal chemistry, 2009, Apr-09, Volume: 52, Issue:7

    Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2 Inhibitors

2009
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Type 2 diabetes: glycemic targets and oral therapies for older patients.
    Geriatrics, 1998, Volume: 53, Issue:11

    Topics: 1-Deoxynojirimycin; Acarbose; Age Factors; Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Metformin; Piperidines; Sulfonylurea Compounds; Trisaccharides

1998
Treatment of diabetes mellitus: implications of the use of oral agents.
    American heart journal, 1999, Volume: 138, Issue:5 Pt 1

    Topics: Acarbose; Administration, Oral; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Insulin; Metformin; Sulfonylurea Compounds; Survival Rate

1999
[Metformin-induced lactic acidosis].
    Deutsche medizinische Wochenschrift (1946), 2000, Mar-03, Volume: 125, Issue:9

    Topics: Acidosis, Lactic; Acute Disease; Coma; Combined Modality Therapy; Contraindications; Diabetes Mellitus, Type 2; Diagnosis, Differential; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Sulfonylurea Compounds

2000
Combining sulfonylureas and other oral agents.
    The American journal of medicine, 2000, Apr-17, Volume: 108 Suppl 6a

    Topics: Acarbose; Administration, Oral; Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glyburide; Humans; Hypoglycemic Agents; Metformin; Piperidines; Sulfonylurea Compounds

2000
[Therapies for newly-onset diabetic patients].
    Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 2

    Topics: Acarbose; Cyclohexanes; Diabetes Mellitus, Type 2; Diet Therapy; Enzyme Inhibitors; Exercise Therapy; Glucose; Glucose Intolerance; Glycogen; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Nateglinide; Phenylalanine; Sulfonylurea Compounds; Thiazolidinediones

2005
Translating science into clinical practice: focus on vildagliptin in combination with metformin.
    Diabetes, obesity & metabolism, 2009, Volume: 11 Suppl 2

    Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Thiazolidinediones; Vildagliptin

2009
Ethnic origin is unrelated to autoimmunity and residual pancreatic function in 471 youth with clinically diagnosed type 2 diabetes.
    Pediatric diabetes, 2009, Volume: 10, Issue:4

    Topics: Administration, Oral; Adolescent; Algorithms; Autoimmunity; Child; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hypoglycemic Agents; Male; Metformin; Pancreas; Sulfonylurea Compounds

2009
Optimizing outcomes for GLP-1 agonists.
    The Journal of the American Osteopathic Association, 2011, Volume: 111, Issue:2 Suppl 1

    Topics: Algorithms; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Male; Metformin; Middle Aged; Peptides; Sulfonylurea Compounds; Treatment Outcome; Venoms

2011
[Incretin-based therapy for treating patients with type 2 diabetes].
    Orvosi hetilap, 2011, Nov-27, Volume: 152, Issue:48

    Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin

2011
A case of hypoglycemic hemiparesis and literature review.
    Upsala journal of medical sciences, 2012, Volume: 117, Issue:3

    Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus; Humans; Hypoglycemia; Male; Metformin; Paresis; Sulfonylurea Compounds

2012
The design of the liraglutide clinical trial programme.
    Diabetes, obesity & metabolism, 2012, Volume: 14 Suppl 2

    Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms

2012
Management of diabetes and pancreatic cancer.
    Oncology nursing forum, 2012, Volume: 39, Issue:5

    Topics: Adenocarcinoma; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Diabetes Mellitus, Type 2; Disease Management; Drug Resistance; Drug Therapy, Combination; Exenatide; Fluorouracil; Humans; Hyperglycemia; Hyperglycemic Hyperosmolar Nonketotic Coma; Hypoglycemic Agents; Insulin; Leucovorin; Male; Malnutrition; Metformin; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Peptides; Sulfonylurea Compounds; Venoms

2012
Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Weight Loss

2013
[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison beween canagliflozin and glimepiride].
    Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139 Suppl 2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Male; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiophenes

2014
Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis.
    International journal of clinical practice, 2015, Volume: 69, Issue:3

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Sulfonylurea Compounds; Treatment Outcome

2015
Updates on Managing Type 2 Diabetes Mellitus with Natural Products: Towards Antidiabetic Drug Development.
    Current medicinal chemistry, 2018, Volume: 25, Issue:39

    Topics: Biological Products; Diabetes Mellitus, Type 2; Drug Discovery; Gliclazide; Glucose Transporter Type 4; Humans; Hypoglycemic Agents; Metformin; Oxidative Stress; Sulfonylurea Compounds

2018
Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    The Cochrane database of systematic reviews, 2016, Oct-17, Volume: 10

    Topics: Adult; Benzamides; Blood Glucose; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Fasting; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Middle Aged; Nateglinide; Phenylalanine; Randomized Controlled Trials as Topic; Sulfonylurea Compounds

2016
Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride.
    Diabetes care, 2018, Volume: 41, Issue:8

    Topics: Adult; Aged; Benzhydryl Compounds; Bone Density; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Randomized Controlled Trials as Topic; Sulfonylurea Compounds

2018
Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials.
    Journal of cellular physiology, 2019, Volume: 234, Issue:3

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Exenatide; Female; Glyburide; Humans; Male; Metformin; Network Meta-Analysis; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Sulfonylurea Compounds; Vildagliptin

2019
Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes.
    Expert review of endocrinology & metabolism, 2019, Volume: 14, Issue:2

    Topics: Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Treatment Outcome

2019
Clinical Evidence and Practice-Based Guidelines on the Utility of Basal Insulin Combined Oral Therapy (Metformin and Glimepiride) in the Current Era.
    Current diabetes reviews, 2023, Volume: 19, Issue:8

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin, Long-Acting; Metformin

2023

Trials

138 trial(s) available for metformin and glimepiride

ArticleYear
Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia.
    Diabetes care, 2001, Volume: 24, Issue:4

    Topics: Aged; Aged, 80 and over; Blood Pressure; Brachial Artery; Diabetes Mellitus, Type 2; Diet, Diabetic; Female; Forearm; Gliclazide; Glyburide; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Ischemia; Male; Metformin; Middle Aged; Reference Values; Regional Blood Flow; Sulfonylurea Compounds; Ultrasonography

2001
Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients.
    Diabetic medicine : a journal of the British Diabetic Association, 2001, Volume: 18, Issue:10

    Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Research Design; Sulfonylurea Compounds

2001
Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients.
    Diabetic medicine : a journal of the British Diabetic Association, 2002, Volume: 19, Issue:2

    Topics: Acetylcholine; Adult; Aged; Blood Flow Velocity; Blood Pressure; Body Mass Index; Body Weight; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Diazoxide; Dipyridamole; Double-Blind Method; Female; Forearm; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Vasodilation

2002
Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients.
    Diabetes care, 2002, Volume: 25, Issue:7

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones

2002
Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double-blind, crossover study.
    British journal of clinical pharmacology, 2003, Volume: 55, Issue:6

    Topics: Aged; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Gliclazide; Humans; Hypoglycemic Agents; Metformin; Microcirculation; Middle Aged; Sulfonylurea Compounds; Vasodilation

2003
Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure.
    Collegium antropologicum, 2003, Volume: 27, Issue:1

    Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Lispro; Male; Metformin; Middle Aged; Postprandial Period; Sulfonylurea Compounds; Treatment Outcome

2003
Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin.
    Diabetes, nutrition & metabolism, 2004, Volume: 17, Issue:3

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Food; Glycated Hemoglobin; Homocysteine; Humans; Hypoglycemic Agents; Lipoprotein(a); Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Sulfonylurea Compounds

2004
Addition of rosiglitazone to glimepirid and metformin combination therapy in type 2 diabetes.
    Endocrine journal, 2004, Volume: 51, Issue:6

    Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides

2004
Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians.
    The Journal of the Association of Physicians of India, 2004, Volume: 52

    Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; India; Insulin; Insulin Resistance; Insulin Secretion; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones

2004
Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
    Diabetes care, 2005, Volume: 28, Issue:2

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Weight Gain

2005
Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
    Pharmacotherapy, 2005, Volume: 25, Issue:5

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinogen; Fibrinolytic Agents; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Tissue Plasminogen Activator

2005
Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes.
    Diabetic medicine : a journal of the British Diabetic Association, 2005, Volume: 22, Issue:8

    Topics: Aged; Asian People; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones

2005
Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Clinical therapeutics, 2005, Volume: 27, Issue:9

    Topics: Analysis of Variance; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metabolic Syndrome; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors

2005
Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Clinical therapeutics, 2005, Volume: 27, Issue:10

    Topics: Adult; Aged; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors

2005
Evaluation of efficacy and safety of fixed dose combination of glimepiride 2 mg pluspioglitazone 15 mg plus metformin SR 500 mg in the management of patients with type-2 diabetes mellitus.
    Journal of the Indian Medical Association, 2005, Volume: 103, Issue:8

    Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones

2005
Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes.
    Diabetes research and clinical practice, 2006, Volume: 72, Issue:3

    Topics: Aged; Blood Glucose; Body Mass Index; Body Weight; Chemotherapy, Adjuvant; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Insulin; Male; Metformin; Middle Aged; Placebos; Sulfonylurea Compounds; Treatment Outcome

2006
Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.
    Diabetes, obesity & metabolism, 2006, Volume: 8, Issue:2

    Topics: Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome

2006
Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Current medical research and opinion, 2006, Volume: 22, Issue:4

    Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome

2006
Glycaemic control without weight gain in insulin requiring type 2 diabetes: 1-year results of the GAME regimen.
    Diabetes, obesity & metabolism, 2006, Volume: 8, Issue:5

    Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Hemoglobins; Humans; Hypoglycemic Agents; Insulin; Insulin Aspart; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Failure; Treatment Outcome; Weight Gain

2006
Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2006, Volume: 114, Issue:9

    Topics: Aged; Biphasic Insulins; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Aspart; Insulin Glargine; Insulin, Isophane; Insulin, Long-Acting; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome

2006
Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Clinical endocrinology, 2007, Volume: 66, Issue:2

    Topics: Adiponectin; Analysis of Variance; Biomarkers; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Administration Schedule; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Interleukin-18; Interleukin-6; Metformin; Multivariate Analysis; Resistin; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Tumor Necrosis Factor-alpha

2007
Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
    Journal of the American Geriatrics Society, 2007, Volume: 55, Issue:2

    Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Sulfonylurea Compounds; Weight Gain

2007
Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study.
    Diabetes care, 2007, Volume: 30, Issue:4

    Topics: Adolescent; Body Mass Index; Child; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Safety; Single-Blind Method; Sulfonylurea Compounds; Weight Gain

2007
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:5

    Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles

2007
Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with Type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot St
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2008, Volume: 116, Issue:1

    Topics: Aged; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Patient Satisfaction; Pilot Projects; Sulfonylurea Compounds; Treatment Outcome

2008
Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switch pilot st
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2007, Volume: 115, Issue:10

    Topics: Administration, Oral; Aged; Blood Glucose; Body Mass Index; Case-Control Studies; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Pilot Projects; Prospective Studies; Sulfonylurea Compounds; Time Factors

2007
Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes - a simulation with the Diabetes Mellitus Model (DMM).
    International journal of clinical pharmacology and therapeutics, 2007, Volume: 45, Issue:12

    Topics: Adult; Aged; Computer Simulation; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Middle Aged; Models, Biological; Sulfonylurea Compounds

2007
Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes.
    Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Rosiglitazone; Single-Blind Method; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triglycerides

2008
Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride.
    Diabetes & vascular disease research, 2008, Volume: 5, Issue:3

    Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipids; Male; Metformin; Middle Aged; Oxazoles; Sulfonylurea Compounds; Time Factors; Treatment Outcome

2008
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
    Diabetes care, 2009, Volume: 32, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Obesity; Placebos; Safety; Sulfonylurea Compounds

2009
Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease.
    Diabetes & vascular disease research, 2008, Volume: 5, Issue:4

    Topics: Adiponectin; Aged; C-Reactive Protein; Diabetes Mellitus, Type 2; Diastole; Drug Therapy, Combination; Echocardiography, Doppler, Pulsed; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Malondialdehyde; Metformin; Middle Aged; Myocardial Contraction; Myocardium; Oxidative Stress; Pilot Projects; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome

2008
Glucose control and vascular complications in veterans with type 2 diabetes.
    The New England journal of medicine, 2009, Jan-08, Volume: 360, Issue:2

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Neuropathies; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; United States; Veterans

2009
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:2

    Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Time Factors; Vildagliptin

2009
Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes.
    Atherosclerosis, 2009, Volume: 205, Issue:1

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome

2009
Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.
    Circulation, 2009, Apr-21, Volume: 119, Issue:15

    Topics: Adenosine Triphosphate; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Acids; Glycated Hemoglobin; Heart; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metabolic Syndrome; Metformin; Middle Aged; Myocardium; Phosphocreatine; Pioglitazone; PPAR alpha; Radionuclide Imaging; Stroke Volume; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides; Ventricular Dysfunction, Left; Ventricular Remodeling

2009
Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Metabolism: clinical and experimental, 2009, Volume: 58, Issue:8

    Topics: Administration, Oral; Adult; Aged; Blood Glucose; Body Mass Index; Caloric Restriction; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Motor Activity; Patient Education as Topic; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Weight Loss; Young Adult

2009
Evaluation of the repaglinide efficiency in comparison to the glimepiride in the type 2 diabetes patients poorly regulated by the metmorfine administration.
    Bratislavske lekarske listy, 2009, Volume: 110, Issue:6

    Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Sulfonylurea Compounds

2009
Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
    Diabetes care, 2010, Volume: 33, Issue:4

    Topics: Adamantane; Diabetes Mellitus, Type 2; Glucagon; Humans; Hypoglycemic Agents; Metformin; Nitriles; Postprandial Period; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin

2010
Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in
    Clinical therapeutics, 2009, Volume: 31, Issue:11

    Topics: Adult; Area Under Curve; Chemistry, Pharmaceutical; Cross-Over Studies; Drug Combinations; Fasting; Half-Life; Humans; Hypoglycemic Agents; Male; Metformin; Sulfonylurea Compounds; Tablets; Young Adult

2009
Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabetes.
    Diabetes care, 2010, Volume: 33, Issue:7

    Topics: Apolipoprotein B-100; Cholesterol; Cholesterol Ester Transfer Proteins; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Liver; Magnetic Resonance Imaging; Male; Metformin; Middle Aged; Pioglitazone; Placebos; Prospective Studies; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides

2010
Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
    Primary care diabetes, 2010, Volume: 4, Issue:2

    Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Patient Satisfaction; Quality of Life; Sulfonylurea Compounds; Treatment Outcome

2010
Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus.
    Clinical science (London, England : 1979), 2010, Jul-09, Volume: 119, Issue:8

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Erythrocyte Deformability; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Stress, Mechanical; Sulfonylurea Compounds; Thiazolidinediones

2010
Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.
    Applied health economics and health policy, 2010, Volume: 8, Issue:4

    Topics: Canada; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Quality-Adjusted Life Years; Sulfonylurea Compounds

2010
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.
    Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:9

    Topics: Adamantane; Adolescent; Adult; Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin; Weight Gain; Young Adult

2010
Comparison of the bioavailability and tolerability of fixed-dose combination glimepiride/metformin 2/500-mg tablets versus separate tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy Korean volunteers.
    Clinical therapeutics, 2010, Volume: 32, Issue:7

    Topics: Adolescent; Adult; Area Under Curve; Asian People; Chromatography, Liquid; Cross-Over Studies; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Korea; Male; Metformin; Sulfonylurea Compounds; Tablets; Tandem Mass Spectrometry; Therapeutic Equivalency; Young Adult

2010
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
    Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:1

    Topics: Adolescent; Adult; Benzhydryl Compounds; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult

2011
Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl
    Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Blood Pressure; China; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; India; Liraglutide; Male; Metformin; Middle Aged; Republic of Korea; Sulfonylurea Compounds; Weight Loss; Young Adult

2011
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.
    Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:2

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles

2011
Evaluation of efficacy and tolerability of glimepiride and metformin combination: a multicentric study in patients with type-2 diabetes mellitus, uncontrolled on monotherapy with sulfonylurea or metformin.
    American journal of therapeutics, 2013, Volume: 20, Issue:1

    Topics: Administration, Oral; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prospective Studies; Sulfonylurea Compounds; Treatment Outcome

2013
PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
    Diabetes technology & therapeutics, 2011, Volume: 13, Issue:6

    Topics: Adiponectin; Aged; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Proinsulin; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides

2011
Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II).
    Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:9

    Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Patient Satisfaction; Pioglitazone; Postprandial Period; Prospective Studies; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome

2011
The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study.
    Journal of diabetes science and technology, 2011, Mar-01, Volume: 5, Issue:2

    Topics: Aged; Biomarkers; Blood Coagulation; Blood Platelets; Body Mass Index; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Inflammation; Ligands; Male; Metformin; Middle Aged; Pioglitazone; Platelet Function Tests; Sulfonylurea Compounds; Thiazolidinediones; Thromboxanes; von Willebrand Factor

2011
Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients.
    European journal of pharmacology, 2011, Volume: 666, Issue:1-3

    Topics: Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Female; Glycated Hemoglobin; Humans; Inflammation; Insulin Resistance; Male; Metformin; Middle Aged; Peptides; Sulfonylurea Compounds; Venoms

2011
Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes.
    Diabetes/metabolism research and reviews, 2012, Volume: 28, Issue:3

    Topics: Administration, Oral; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Models, Biological; Sulfonylurea Compounds

2012
Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized
    Clinical therapeutics, 2011, Volume: 33, Issue:11

    Topics: Adult; Chromatography, Liquid; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Half-Life; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Reference Values; Sulfonylurea Compounds; Tandem Mass Spectrometry

2011
Effects of pioglitazone and metformin on vascular endothelial function in patients with type 2 diabetes treated with sulfonylureas.
    Diabetes & vascular disease research, 2012, Volume: 9, Issue:1

    Topics: Aged; Biomarkers; Brachial Artery; Chi-Square Distribution; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelium, Vascular; Female; Glycated Hemoglobin; Greece; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Treatment Outcome; Ultrasonography, Doppler; Vasodilation

2012
Pharmacokinetics of a fixed-dose glimepiride/sustained-release metformin combination.
    International journal of clinical pharmacology and therapeutics, 2012, Volume: 50, Issue:2

    Topics: Adult; Analysis of Variance; Area Under Curve; Biological Availability; Chromatography, Liquid; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Humans; Hypoglycemic Agents; Male; Metformin; Sulfonylurea Compounds; Tablets; Tandem Mass Spectrometry; Young Adult

2012
Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jun-16, Volume: 379, Issue:9833

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Risk Factors; Sulfonylurea Compounds; Treatment Failure; Venoms; Young Adult

2012
Effects of frequency of follow-up on quality of life of type 2 diabetes patients on oral hypoglycemics.
    Diabetes technology & therapeutics, 2012, Volume: 14, Issue:9

    Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Patient Selection; Precision Medicine; Quality of Life; Sulfonylurea Compounds

2012
Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research.
    Diabetes & vascular disease research, 2013, Volume: 10, Issue:1

    Topics: Aged; Blood Flow Velocity; Brachial Artery; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Electrocardiography; Endothelium, Vascular; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Receptors, Glucagon; Sulfonylurea Compounds; Ultrasonography, Doppler; Vasodilation; Venoms

2013
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
    Lancet (London, England), 2012, Aug-04, Volume: 380, Issue:9840

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Research Design; Sulfonylurea Compounds; Treatment Failure; Treatment Outcome

2012
Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?
    Diabetes technology & therapeutics, 2012, Volume: 14, Issue:10

    Topics: Adamantane; Adult; Aged; Analysis of Variance; Area Under Curve; Basal Metabolism; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrazines; Pyrrolidines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin

2012
Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
    The Journal of the Association of Physicians of India, 2012, Volume: 60

    Topics: Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Time Factors; Treatment Outcome; Triazoles

2012
Effect of pioglitazone on testosterone in eugonadal men with type 2 diabetes mellitus: a randomized double-blind placebo-controlled study.
    Clinical endocrinology, 2013, Volume: 78, Issue:3

    Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Testosterone; Thiazolidinediones

2013
Metformin, but not glimepiride, improves carotid artery diameter and blood flow in patients with type 2 diabetes mellitus.
    Clinics (Sao Paulo, Brazil), 2012, Volume: 67, Issue:7

    Topics: Blood Glucose; Carotid Arteries; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Organ Size; Prospective Studies; Sulfonylurea Compounds

2012
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Sulfonylurea Compounds; Treatment Outcome

2012
Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes.
    International journal of clinical practice, 2013, Volume: 67, Issue:3

    Topics: Adult; Aged; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Medication Adherence; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome

2013
Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:6

    Topics: Adamantane; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Nitriles; Postprandial Period; Proinsulin; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin

2013
Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus.
    Diabetes technology & therapeutics, 2013, Volume: 15, Issue:4

    Topics: Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles

2013
Vildagliptin more effectively achieves a composite endpoint of HbA₁c < 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment.
    Diabetes research and clinical practice, 2013, Volume: 100, Issue:3

    Topics: Adamantane; Aged; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin; Weight Gain

2013
Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study.
    Cardiovascular diabetology, 2013, Apr-08, Volume: 12

    Topics: Adamantane; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Erythrocyte Deformability; Female; Germany; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Laser-Doppler Flowmetry; Male; Metformin; Microcirculation; Middle Aged; Nitriles; Pyrrolidines; Regional Blood Flow; Retinal Vessels; Sulfonylurea Compounds; Time Factors; Treatment Outcome; Vildagliptin

2013
Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical tri
    Diabetologia, 2013, Volume: 56, Issue:7

    Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles; Young Adult

2013
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).
    Diabetes care, 2013, Volume: 36, Issue:8

    Topics: Adult; Blood Glucose; Comparative Effectiveness Research; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Outcome Assessment, Health Care; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles

2013
Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:12

    Topics: Adamantane; Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin; Young Adult

2013
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
    Lancet (London, England), 2013, Sep-14, Volume: 382, Issue:9896

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Young Adult

2013
Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
    Cardiovascular diabetology, 2013, Sep-05, Volume: 12

    Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Pressure; Body Mass Index; Clinical Protocols; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Research Design; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Time Factors; Treatment Outcome

2013
Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
    Diabetes/metabolism research and reviews, 2014, Volume: 30, Issue:7

    Topics: Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Linagliptin; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Postprandial Period; Proinsulin; Purines; Quinazolines; Risk Factors; Sulfonylurea Compounds

2014
Adding glimepiride to insulin+metformin in type 2 diabetes of more than 10 years' duration--a randomised, double-blind, placebo-controlled, cross-over study.
    Diabetes research and clinical practice, 2014, Volume: 103, Issue:2

    Topics: Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Postprandial Period; Sulfonylurea Compounds; Treatment Outcome

2014
Both glimepiride and high-dose metformin are important for sustained glucose lowering in Japanese type 2 diabetes patients on glimepiride-sitagliptin-metformin therapy: subanalysis of a single-center, open-label, randomized study.
    Diabetes technology & therapeutics, 2014, Volume: 16, Issue:7

    Topics: Administration, Oral; Aged; Aged, 80 and over; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles

2014
Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin Glargine; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Young Adult

2014
Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone.
    Current medical research and opinion, 2014, Volume: 30, Issue:7

    Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hydroxychloroquine; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Young Adult

2014
Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes.
    Diabetic medicine : a journal of the British Diabetic Association, 2014, Volume: 31, Issue:12

    Topics: Adamantane; Adiponectin; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dietary Fats; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Male; Metformin; Middle Aged; Nitriles; Proinsulin; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Triglycerides; Tumor Necrosis Factor-alpha; Vildagliptin

2014
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
    Metabolism: clinical and experimental, 2014, Volume: 63, Issue:7

    Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hyperlipidemias; Hypoglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Intention to Treat Analysis; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin; Weight Gain; Weight Loss

2014
HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
    Diabetes care, 2014, Volume: 37, Issue:8

    Topics: Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles

2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Treatment Outcome

2014
Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:1

    Topics: Aged; Asia; Blood Glucose Self-Monitoring; Circadian Rhythm; Diabetes Mellitus, Type 2; Drug Dosage Calculations; Drug Resistance; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin, Isophane; Insulin, Long-Acting; Male; Metformin; Middle Aged; Middle East; South Africa; Sulfonylurea Compounds

2015
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
    Diabetes care, 2015, Volume: 38, Issue:3

    Topics: Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiophenes; Time Factors; Treatment Outcome; Weight Loss

2015
Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:2

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome

2015
Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION).
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:7

    Topics: Adamantane; Age Factors; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Metformin; Sulfonylurea Compounds; Treatment Outcome

2015
Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:7

    Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Europe; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Peptides; Prospective Studies; Sulfonylurea Compounds; Thiazolidinediones; Treatment Failure; Venoms

2015
Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes.
    Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:8

    Topics: Aged; Benzofurans; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucokinase; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrimidines; Sitagliptin Phosphate; Sulfonylurea Compounds

2015
Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males.
    Advances in therapy, 2015, Volume: 32, Issue:5

    Topics: 1-Deoxynojirimycin; Adult; Antihypertensive Agents; Area Under Curve; Cross-Over Studies; Female; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sorbitol; Sulfonylurea Compounds; Thiazolidinediones; Triazoles

2015
Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).
    Diabetes care, 2015, Volume: 38, Issue:12

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastrointestinal Diseases; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin Glargine; Male; Metformin; Middle Aged; Recombinant Fusion Proteins; Sulfonylurea Compounds; Treatment Outcome; Weight Loss

2015
A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
    Drug research, 2016, Volume: 66, Issue:2

    Topics: 1-Deoxynojirimycin; Adult; Benzhydryl Compounds; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Interactions; Glucose; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Inositol; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Urine; Young Adult

2016
Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.
    Cardiovascular diabetology, 2015, Sep-04, Volume: 14

    Topics: Aged; Biomarkers; Blood Glucose; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Europe; Exenatide; Female; Glycated Hemoglobin; Heart Rate; Humans; Hypoglycemic Agents; Incretins; Lipids; Male; Metformin; Middle Aged; Peptides; Risk Factors; Sulfonylurea Compounds; Time Factors; Treatment Outcome; Venoms

2015
Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus.
    Pakistan journal of pharmaceutical sciences, 2015, Volume: 28, Issue:5

    Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Folic Acid; Gliclazide; Glycated Hemoglobin; Homocysteine; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Risk Factors; Sulfonylurea Compounds

2015
Open-label randomized non-inferiority trial of a fixed-dose combination of glimepiride and atorvastatin for the treatment of people whose Type 2 diabetes is uncontrolled on metformin.
    Diabetic medicine : a journal of the British Diabetic Association, 2016, Volume: 33, Issue:8

    Topics: Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds

2016
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Latin America; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome

2016
Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin.
    Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:5

    Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Interactions; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Ranolazine; Sodium Channel Blockers; Sulfonylurea Compounds

2016
[New attempt in a benefit evaluation].
    MMW Fortschritte der Medizin, 2015, Dec-14, Volume: 157, Issue:21-22

    Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Metformin; Sulfonylurea Compounds

2015
Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
    Cardiovascular diabetology, 2016, Apr-04, Volume: 15

    Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality of Life; Sulfonylurea Compounds

2016
Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.
    Journal of diabetes, 2017, Volume: 9, Issue:4

    Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Infections; Male; Metformin; Middle Aged; Nausea; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome

2017
Hypoglycemia in Frail Elderly Patients With Type 2 Diabetes Mellitus Treated With Sulfonylurea.
    Journal of diabetes science and technology, 2017, Volume: 11, Issue:2

    Topics: Aged; Aged, 80 and over; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Female; Frail Elderly; Gliclazide; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Sulfonylurea Compounds

2017
A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1).
    PloS one, 2016, Volume: 11, Issue:10

    Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Antioxidants; Biomarkers; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Drug Administration Schedule; Endothelium; Female; Glycated Hemoglobin; Hemodynamics; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Superoxide Dismutase; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult

2016
Effects of Glimepiride versus Saxagliptin on β-Cell Function and Hypoglycemia: A Post Hoc Analysis in Older Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
    Clinical therapeutics, 2016, Volume: 38, Issue:12

    Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Risk Factors; Sulfonylurea Compounds; Treatment Outcome

2016
Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study).
    Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:6

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrimidines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Young Adult

2017
A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
    Cardiovascular diabetology, 2017, 01-21, Volume: 16, Issue:1

    Topics: Aged; Biomarkers; Brachial Artery; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Microcirculation; Microvessels; Middle Aged; Sulfonylurea Compounds; Time Factors; Treatment Outcome; Vasodilation

2017
Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial.
    Science China. Life sciences, 2017, Volume: 60, Issue:3

    Topics: Acarbose; Adult; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome

2017
The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:12

    Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dinoprost; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin

2017
A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.
    BMC endocrine disorders, 2017, Nov-06, Volume: 17, Issue:1

    Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Heterocyclic Compounds, 2-Ring; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrans; Sulfonylurea Compounds

2017
Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:5

    Topics: Adult; Diabetes Mellitus, Type 2; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Hospitals, University; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Outpatient Clinics, Hospital; Republic of Korea; Sulfonylurea Compounds

2018
Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.
    Metabolism: clinical and experimental, 2018, Volume: 85

    Topics: Adiponectin; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Leptin; Male; Metformin; Middle Aged; Molybdoferredoxin; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Treatment Outcome; Tumor Necrosis Factor-alpha

2018
Comparison of Adherence to Glimepiride/Metformin Sustained Release Once-daily Versus Glimepiride/Metformin Immediate Release BID Fixed-combination Therapy Using the Medication Event Monitoring System in Patients With Type 2 Diabetes.
    Clinical therapeutics, 2018, Volume: 40, Issue:5

    Topics: Aged; Body Mass Index; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Medication Adherence; Metformin; Middle Aged; Republic of Korea; Sulfonylurea Compounds

2018
Pharmacoeconomic evaluation of glimepiride combined with other drugs in the treatment of diabetes.
    Pakistan journal of pharmaceutical sciences, 2018, Volume: 31, Issue:3(Special)

    Topics: Acarbose; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds

2018
Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects.
    Clinical pharmacology in drug development, 2019, Volume: 8, Issue:3

    Topics: Adolescent; Adult; Bridged Bicyclo Compounds, Heterocyclic; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Female; Glucuronosyltransferase; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sulfonylurea Compounds; UDP-Glucuronosyltransferase 1A9; Young Adult

2019
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:11

    Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome; Urinary Tract Infections

2018
Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:12

    Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Time Factors; Treatment Outcome

2018
Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:3

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazoles; Republic of Korea; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidines; Treatment Failure

2019
Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centr
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:4

    Topics: Adamantane; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Sulfonylurea Compounds; Weight Gain

2019
Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:4

    Topics: Aged; Blood Glucose; Bone Density; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Mycoses; Reproductive Tract Infections; Sulfonylurea Compounds; Vulvovaginitis

2019
Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients.
    The Journal of the Association of Physicians of India, 2018, Volume: 66, Issue:8

    Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Nitriles; Prospective Studies; Pyrrolidines; Quality of Life; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin

2018
A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy.
    Diabetes research and clinical practice, 2019, Volume: 155

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Prognosis; Safety; Sulfonylurea Compounds

2019
Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
    Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:7

    Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome

2020
Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24-week, open-label, controlled trial (STOP-OB).
    Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:9

    Topics: Administration, Oral; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Metformin; Sulfonylurea Compounds; Treatment Outcome

2020
Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs.
    Journal of endocrinological investigation, 2021, Volume: 44, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antimalarials; Biomarkers; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prognosis; Sulfonylurea Compounds; Young Adult

2021
Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial.
    Diabetes care, 2020, Volume: 43, Issue:11

    Topics: Adult; Aged; Chemokine CXCL12; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Kidney; Linagliptin; Male; Metformin; Middle Aged; Natriuresis; Overweight; Sulfonylurea Compounds; Treatment Outcome

2020
Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease.
    Diabetes research and clinical practice, 2020, Volume: 170

    Topics: Adiponectin; Atherosclerosis; Biomarkers; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Interleukin-1beta; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thrombosis; Vildagliptin

2020
Effect of Dosage Reduction of Hypoglycemic Multidrug Regimens on the Incidences of Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramaḍān: A Randomized Controlled Trial.
    Frontiers in endocrinology, 2021, Volume: 12

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycemic Control; Humans; Hypoglycemic Agents; Insulin Glargine; Islam; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Vildagliptin

2021
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.
    Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:1

    Topics: Adamantane; Adipose Tissue; Adolescent; Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver; Magnetic Resonance Imaging; Metformin; Sulfonylurea Compounds; Treatment Outcome

2022
Analysis of pharmacoeconomic value of sitagliptin in the treatment of diabetes mellitus.
    European review for medical and pharmacological sciences, 2021, Volume: 25, Issue:22

    Topics: Adult; Aged; Aged, 80 and over; Cost-Benefit Analysis; Diabetes Mellitus; Economics, Pharmaceutical; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds

2021
Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.
    Cardiovascular diabetology, 2021, 12-17, Volume: 20, Issue:1

    Topics: Aged; Biomarkers; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Lipidomics; Lipids; Liraglutide; Male; Metabolome; Metabolomics; Metformin; Middle Aged; Spectrometry, Mass, Electrospray Ionization; Sulfonylurea Compounds; Time Factors; Treatment Outcome

2021
Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study.
    Diabetes & metabolism journal, 2022, Volume: 46, Issue:5

    Topics: Autoimmune Diseases; Blood Glucose; Blood Glucose Self-Monitoring; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Lipoproteins, HDL; Metformin; Pioglitazone; Piperidines; Sulfonylurea Compounds; Treatment Outcome; Uracil

2022
Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
    The New England journal of medicine, 2022, 09-22, Volume: 387, Issue:12

    Topics: Blood Glucose; Comparative Effectiveness Research; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome

2022
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
    The New England journal of medicine, 2022, 09-22, Volume: 387, Issue:12

    Topics: Albuminuria; Blood Glucose; Cardiovascular Diseases; Comparative Effectiveness Research; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Drug Therapy, Combination; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heart Failure; Humans; Hypertension; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Microvessels; Sitagliptin Phosphate; Sulfonylurea Compounds

2022
Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study.
    Nutrients, 2023, Jan-03, Volume: 15, Issue:1

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gastrointestinal Microbiome; Glucose; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Intestines; Metformin; Middle Aged; Obesity; Treatment Outcome; Weight Gain

2023
Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi-heart study.
    Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:8

    Topics: Aged; Diabetes Mellitus, Type 2; Echocardiography; Female; Heart; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Prospective Studies; Pyrimidines; Sulfonylurea Compounds

2023
Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
    JAMA internal medicine, 2023, 07-01, Volume: 183, Issue:7

    Topics: Adult; Albuminuria; Diabetes Mellitus, Type 2; Disease Progression; Female; Glomerular Filtration Rate; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Kidney; Kidney Diseases; Liraglutide; Male; Metformin; Middle Aged; Sitagliptin Phosphate

2023
The effects of early short-term insulin treatment vs. glimepiride on beta cell function in newly diagnosed type 2 diabetes with HbA1c above 9.
    Turkish journal of medical sciences, 2023, Volume: 53, Issue:2

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Metformin

2023

Other Studies

88 other study(ies) available for metformin and glimepiride

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Study on the synthesis and biological activities of α-substituted arylacetates derivatives.
    Bioorganic & medicinal chemistry letters, 2016, Apr-01, Volume: 26, Issue:7

    Topics: Acetates; alpha-Glucosidases; Animals; Antineoplastic Agents; Cell Line, Tumor; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Neoplasms; Rats; Solanaceous Alkaloids; Structure-Activity Relationship

2016
Prevention of weight gain in type 2 diabetes requiring insulin treatment.
    Diabetes, obesity & metabolism, 2004, Volume: 6, Issue:2

    Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pilot Projects; Sulfonylurea Compounds; Weight Gain

2004
Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes.
    Diabetes research and clinical practice, 2004, Volume: 64, Issue:3

    Topics: Arteriosclerosis; Carotid Arteries; Carotid Artery Diseases; Chronic Disease; Diabetes Mellitus, Type 2; Diet Therapy; Drug Administration Schedule; Female; Gliclazide; Glyburide; Glycated Hemoglobin; Humans; Japan; Male; Metformin; Middle Aged; Prospective Studies; Sulfonylurea Compounds; Time Factors; Tunica Intima; Tunica Media

2004
Low-dose metformin improves hyperglycaemia related to myotonic dystrophy.
    Diabetic medicine : a journal of the British Diabetic Association, 2005, Volume: 22, Issue:3

    Topics: Blood Glucose; C-Peptide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Middle Aged; Myotonic Dystrophy; Sulfonylurea Compounds

2005
[Effects of glimepiride and metformin on free fatty acid in patients with Type 2 diabetes mellitus].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2004, Volume: 29, Issue:6

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Humans; Insulin Resistance; Male; Metformin; Middle Aged; Sulfonylurea Compounds

2004
Simultaneous determination of metformin and glimepride in pharmaceutical dosage form by reverse-phase liquid chromatography.
    Journal of separation science, 2005, Volume: 28, Issue:16

    Topics: Chromatography, Liquid; Metformin; Sulfonylurea Compounds

2005
Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial.
    The European journal of health economics : HEPAC : health economics in prevention and care, 2008, Volume: 9, Issue:2

    Topics: Administration, Oral; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Germany; Health Care Costs; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; National Health Programs; Randomized Controlled Trials as Topic; Sulfonylurea Compounds

2008
Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France.
    Diabetes, obesity & metabolism, 2008, Volume: 10 Suppl 1

    Topics: Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; France; Glipizide; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality of Life; Stress, Psychological; Sulfonylurea Compounds

2008
Simultaneous estimation of metformin hydrochloride, pioglitazone hydrochloride, and glimepiride by RP-HPLC in tablet formulation.
    Journal of chromatographic science, 2008, Volume: 46, Issue:6

    Topics: Chromatography, High Pressure Liquid; Hypoglycemic Agents; Metformin; Pioglitazone; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sulfonylurea Compounds; Tablets; Thiazolidinediones

2008
Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.
    The Journal of pharmacy and pharmacology, 2008, Volume: 60, Issue:9

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metformin; Mice; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Simvastatin; Streptozocin; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides

2008
Exenatide and acute pancreatitis.
    The Journal of the Association of Physicians of India, 2008, Volume: 56

    Topics: Acute Disease; Diabetes Mellitus, Type 2; Drug Interactions; Exenatide; Female; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Metformin; Middle Aged; Pancreatitis; Peptides; Sulfonylurea Compounds; Venoms

2008
Lost in translation: modulation of the metabolic-functional relation in the diabetic human heart.
    Circulation, 2009, Apr-21, Volume: 119, Issue:15

    Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty Acids; Female; Heart; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Metformin; Myocardium; Oxidation-Reduction; Pioglitazone; PPAR alpha; Sulfonylurea Compounds; Thiazolidinediones; Ventricular Dysfunction, Left

2009
The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics.
    Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Sulfonylurea Compounds; Venoms; Young Adult

2009
Triple verses glimepiride plus metformin therapy on cardiovascular risk biomarkers and diabetic cardiomyopathy in insulin resistance type 2 diabetes mellitus rats.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2009, Dec-08, Volume: 38, Issue:5

    Topics: Animals; Biomarkers; Cardiomyopathies; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Insulin Resistance; Male; Metformin; Rats; Rats, Wistar; Risk Factors; Sulfonylurea Compounds

2009
Remission of diabetes mellitus type 2 with severe hyperglycemia after Exenatide treatment.
    Diabetes research and clinical practice, 2010, Volume: 90, Issue:3

    Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Metformin; Middle Aged; Obesity; Peptides; Remission Induction; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Venoms; Weight Loss

2010
Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
    Clinical therapeutics, 2010, Volume: 32, Issue:10

    Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Models, Econometric; Peptides; Quality-Adjusted Life Years; Statistics, Nonparametric; Sulfonylurea Compounds; United States; Venoms

2010
[Effect of short-term intensive therapy with glimepiride and metformin in newly diagnosed type 2 diabetic patients].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2011, Volume: 31, Issue:3

    Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Male; Metformin; Sulfonylurea Compounds; Treatment Outcome

2011
Reduced cell proliferation and neuroblast differentiation in the dentate gyrus of high fat diet-fed mice are ameliorated by metformin and glimepiride treatment.
    Neurochemical research, 2011, Volume: 36, Issue:12

    Topics: Animals; Body Weight; Brain-Derived Neurotrophic Factor; Cell Differentiation; Cell Proliferation; Dentate Gyrus; Diet, Fat-Restricted; Diet, High-Fat; Doublecortin Domain Proteins; Doublecortin Protein; Eating; Ki-67 Antigen; Male; Metformin; Mice; Mice, Inbred C57BL; Microtubule-Associated Proteins; Neuropeptides; Receptor, trkB; Sulfonylurea Compounds

2011
The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
    Diabetic medicine : a journal of the British Diabetic Association, 2012, Volume: 29, Issue:8

    Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Retrospective Studies; Risk Factors; Sulfonylurea Compounds

2012
Investigation of an active film coating to prepare new fixed-dose combination tablets for treatment of diabetes.
    International journal of pharmaceutics, 2012, May-10, Volume: 427, Issue:2

    Topics: Adult; Algorithms; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Diabetes Mellitus; Drug Combinations; Drug Compounding; Drug Industry; Drug Stability; Excipients; Humans; Hypoglycemic Agents; Male; Metformin; Solubility; Spectroscopy, Near-Infrared; Sulfonylurea Compounds; Suspensions; Tablets

2012
Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.
    Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:9

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Propensity Score; Retrospective Studies; Sulfonylurea Compounds; Young Adult

2012
Multiple cerebral infarctions related to famotidine-induced eosinophilia.
    Journal of neurology, 2012, Volume: 259, Issue:10

    Topics: Acarbose; Adrenergic alpha-1 Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antihypertensive Agents; Aspirin; Calcium Channel Blockers; Cerebral Infarction; Diabetes Mellitus, Type 2; Diffusion Magnetic Resonance Imaging; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Famotidine; Humans; Hypertension; Hypoglycemic Agents; Labetalol; Male; Metformin; Middle Aged; Nifedipine; Peptic Ulcer; Prazosin; Sulfonylurea Compounds

2012
Gliptin versus a sulphonylurea as add-on to metformin.
    Lancet (London, England), 2012, Aug-04, Volume: 380, Issue:9840

    Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Purines; Quinazolines; Sulfonylurea Compounds

2012
Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis.
    Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:1

    Topics: Blood Glucose; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Germany; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Medication Adherence; Metformin; Middle Aged; Primary Health Care; Retrospective Studies; Sulfonylurea Compounds

2013
Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?
    Nature reviews. Endocrinology, 2012, Volume: 8, Issue:10

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Purines; Quinazolines; Sulfonylurea Compounds

2012
Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
    International journal of technology assessment in health care, 2012, Volume: 28, Issue:4

    Topics: China; Confidence Intervals; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Health Care Costs; Humans; Hypoglycemic Agents; Life Expectancy; Liraglutide; Metformin; Models, Economic; Quality-Adjusted Life Years; Sulfonylurea Compounds

2012
[Continuous glucose monitoring in glimipiride plus metformin treated type 2 diabetic patients during the month of Ramadan].
    La Tunisie medicale, 2012, Volume: 90, Issue:10

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Humans; Hypoglycemic Agents; Islam; Male; Metformin; Middle Aged; Monitoring, Ambulatory; Sulfonylurea Compounds; Tunisia

2012
[SGLT-2-inhibitor dapagliflozin: new treatment approach for diabetes type 2--new achievements, but also new questions!].
    Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138 Suppl 1

    Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glipizide; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Metformin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds

2013
Inflammation and cognitive dysfunction in type 2 diabetic carotid endarterectomy patients.
    Diabetes care, 2013, Volume: 36, Issue:10

    Topics: Aged; Cognition Disorders; Diabetes Mellitus, Type 2; Endarterectomy, Carotid; Glyburide; Humans; Hypoglycemic Agents; Inflammation; Logistic Models; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles

2013
RP-LC simultaneous quantitation of co-administered drugs for (non-insulin dependent) diabetic mellitus induced dyslipidemia in active pharmaceutical ingredient, pharmaceutical formulations and human serum with UV-detector.
    Clinica chimica acta; international journal of clinical chemistry, 2013, Oct-21, Volume: 425

    Topics: Adult; Anticholesteremic Agents; Calibration; Chromatography, Reverse-Phase; Diabetes Mellitus, Type 2; Dyslipidemias; Fluorobenzenes; Healthy Volunteers; Humans; Hypoglycemic Agents; Limit of Detection; Male; Metformin; Pyrimidines; Quality Control; Rosuvastatin Calcium; Sulfonamides; Sulfonylurea Compounds; Ultraviolet Rays

2013
Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus.
    Diabetes/metabolism research and reviews, 2013, Volume: 29, Issue:8

    Topics: Administration, Oral; Adult; Aged; Cardiovascular Diseases; Cohort Studies; Comorbidity; Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glyburide; Humans; Hypertension; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Retrospective Studies; Sulfonylurea Compounds; Taiwan

2013
How to prevent and treat pharmacological hypoglycemias.
    Revista clinica espanola, 2014, Volume: 214, Issue:4

    Topics: Anticholesteremic Agents; Antihypertensive Agents; Diabetes Mellitus, Type 2; Female; Humans; Hypercholesterolemia; Hypertension; Hypoglycemia; Hypoglycemic Agents; Metformin; Middle Aged; Sulfonylurea Compounds

2014
Persistent impaired glucose metabolism in a zebrafish hyperglycemia model.
    Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology, 2014, Volume: 171

    Topics: Animals; Disease Models, Animal; Eye Proteins; Glucose; Glycosylation; Hyperglycemia; Hypoglycemic Agents; Insulin; Metformin; Muscle, Skeletal; Receptor, Insulin; Sulfonylurea Compounds; Zebrafish

2014
Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
    Journal of medical economics, 2014, Volume: 17, Issue:9

    Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Health Services; Humans; Hypoglycemic Agents; Life Expectancy; Liraglutide; Male; Metformin; Middle Aged; Models, Economic; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Smoking; Sulfonylurea Compounds; Sweden; Triazoles

2014
A simple and convenient method for the simultaneous in vitro study of metformin and glimepiride tablets.
    Pakistan journal of pharmaceutical sciences, 2014, Volume: 27, Issue:6

    Topics: Chromatography, High Pressure Liquid; Drug Combinations; Hypoglycemic Agents; Metformin; Solubility; Sulfonylurea Compounds; Tablets

2014
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
    Diabetes research and clinical practice, 2015, Volume: 107, Issue:1

    Topics: Aged; Carbamates; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Morbidity; Myocardial Infarction; Piperidines; Registries; Retrospective Studies; Risk Factors; Stroke; Sulfonylurea Compounds; Tolbutamide

2015
A toxicology study to evaluate the embryotoxicity of metformin compared with the hypoglycemic drugs, the anticancer drug, the anti-epileptic drug, the antibiotic, and the cyclo-oxygenase (COX)-2 inhibitor.
    Journal of diabetes, 2015, Volume: 7, Issue:6

    Topics: 3T3 Cells; Animals; Anti-Bacterial Agents; Anticonvulsants; Antineoplastic Agents; Cell Differentiation; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Embryonic Stem Cells; Fibroblasts; Fluorouracil; Gene Expression Regulation, Developmental; Hypoglycemic Agents; Metformin; Mice; Penicillins; Phenytoin; Risk Assessment; Rosiglitazone; Sulfonamides; Sulfonylurea Compounds; Thiazolidinediones

2015
[Fixed-dose combination].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:3

    Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Inositol; Isoindoles; Metformin; Pioglitazone; Piperidines; Sulfonylurea Compounds; Thiazolidinediones; Uracil

2015
Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy.
    Diabetes technology & therapeutics, 2015, Volume: 17, Issue:7

    Topics: Aged; Blood Glucose; Blood Glucose Self-Monitoring; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Retrospective Studies; Sex Factors; Sulfonylurea Compounds; Treatment Outcome; Waist Circumference

2015
Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
    Journal of medical economics, 2015, Volume: 18, Issue:10

    Topics: Adamantane; Body Mass Index; Cardiovascular Diseases; China; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Female; Hospital Costs; Humans; Hypoglycemia; Hypoglycemic Agents; Insurance Claim Review; Kidney Diseases; Male; Metformin; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Sulfonylurea Compounds

2015
New Salting Out Stability-Indicating and Kinetic Thin Layer Chromatographic Method for Determination of Glimepiride and Metformin HCl Binary Mixture.
    Journal of chromatographic science, 2015, Volume: 53, Issue:9

    Topics: Calibration; Chromatography, Thin Layer; Drug Stability; Limit of Detection; Linear Models; Metformin; Reproducibility of Results; Sulfonylurea Compounds; Tablets

2015
Type 2 diabetes alters metabolic and transcriptional signatures of glucose and amino acid metabolism during exercise and recovery.
    Diabetologia, 2015, Volume: 58, Issue:8

    Topics: Amino Acids; Blood Glucose; Calorimetry, Indirect; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Exercise; Glucose; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Muscle, Skeletal; Oxygen Consumption; Sulfonylurea Compounds

2015
Genotoxicity evaluation of metformin and glimepiride by micronucleus assay in exfoliated urothelial cells of type 2 diabetes mellitus patients.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2015, Volume: 83

    Topics: Adult; Aged; Biomarkers; Diabetes Mellitus, Type 2; DNA Damage; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Leukocytes, Mononuclear; Male; Metformin; Micronucleus Tests; Middle Aged; Mutagens; Risk; Sex Characteristics; Sulfonylurea Compounds; Urologic Neoplasms; Urothelium

2015
Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride.
    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2016, Volume: 25, Issue:5

    Topics: Adult; Benzhydryl Compounds; Clinical Protocols; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Personal Satisfaction; Quality of Life; Sulfonylurea Compounds; Treatment Outcome

2016
The effect of testosterone on cardiovascular risk factors in men with type 2 diabetes and late-onset hypogonadism treated with metformin or glimepiride.
    Pharmacological reports : PR, 2016, Volume: 68, Issue:1

    Topics: Aged; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Hypogonadism; Injections, Intramuscular; Male; Metformin; Middle Aged; Risk Factors; Sulfonylurea Compounds; Testosterone; Treatment Outcome

2016
Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
    Postgraduate medicine, 2016, Volume: 128, Issue:4

    Topics: Adiposity; Aged; Body Composition; Body Mass Index; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Time Factors; Waist Circumference; Weight Loss

2016
Simultaneous Determination of Metformin, Glipizide, Repaglinide, and Glimepiride or Metformin and Pioglitazone by a Validated LC Method: Application in the Presence of Metformin Impurity (1-Cyanoguanidine).
    Journal of AOAC International, 2016, Volume: 99, Issue:4

    Topics: Carbamates; Chromatography, High Pressure Liquid; Drug Contamination; Glipizide; Guanidines; Hypoglycemic Agents; Metformin; Pioglitazone; Piperidines; Sulfonylurea Compounds; Thiazolidinediones

2016
A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.
    BMC health services research, 2016, 08-05, Volume: 16, Issue:a

    Topics: Aged; Blood Glucose; Blood Pressure Determination; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality Indicators, Health Care; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiophenes; Treatment Outcome

2016
Evaluation, efficacy and tolerability of GlucoNovax tablet in type 2 diabetic patients.
    Pakistan journal of pharmaceutical sciences, 2016, Volume: 29, Issue:4 Suppl

    Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality of Life; Sulfonylurea Compounds; Tablets; Treatment Outcome

2016
Type 2 diabetes and metabolic syndrome - adipokine levels and effect of drugs.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2017, Volume: 33, Issue:1

    Topics: Adiponectin; Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Leptin; Male; Metabolic Syndrome; Metformin; Middle Aged; Resistin; Sulfonylurea Compounds

2017
Urinary Metabolomic Profiling in Zucker Diabetic Fatty Rats with Type 2 Diabetes Mellitus Treated with Glimepiride, Metformin, and Their Combination.
    Molecules (Basel, Switzerland), 2016, Oct-31, Volume: 21, Issue:11

    Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Metabolome; Metabolomics; Metformin; Rats; Rats, Zucker; Sulfonylurea Compounds

2016
Development of a Novel Zebrafish Model for Type 2 Diabetes Mellitus.
    Scientific reports, 2017, 05-03, Volume: 7, Issue:1

    Topics: Animals; Animals, Genetically Modified; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet; Fasting; Gene Expression Profiling; Gene Expression Regulation; Glucose Tolerance Test; Humans; Hyperglycemia; Hyperphagia; Hypoglycemic Agents; Insulin; Liver; Metformin; Pancreas; Sulfonylurea Compounds; Zebrafish

2017
Once-weekly oral antidiabetic agent and treatment satisfaction.
    Current medical research and opinion, 2017, Volume: 33, Issue:11

    Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Heterocyclic Compounds, 2-Ring; Humans; Hypoglycemic Agents; Metformin; Personal Satisfaction; Pyrans; Sulfonylurea Compounds

2017
Once-weekly oral antidiabetic agent and treatment satisfaction.
    Current medical research and opinion, 2017, Volume: 33, Issue:11

    Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Heterocyclic Compounds, 2-Ring; Humans; Hypoglycemic Agents; Metformin; Personal Satisfaction; Pyrans; Sulfonylurea Compounds

2017
A 3D printed bilayer oral solid dosage form combining metformin for prolonged and glimepiride for immediate drug delivery.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2018, Jul-30, Volume: 120

    Topics: Administration, Oral; Crystallization; Crystallography, X-Ray; Delayed-Action Preparations; Dosage Forms; Drug Carriers; Drug Combinations; Drug Compounding; Drug Liberation; Hypoglycemic Agents; Kinetics; Metformin; Polymers; Polyvinyl Alcohol; Printing, Three-Dimensional; Solubility; Sulfonylurea Compounds; Technology, Pharmaceutical; X-Ray Microtomography

2018
Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity.
    Andrologia, 2018, Volume: 50, Issue:7

    Topics: Adult; Anti-Obesity Agents; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Sexual Dysfunction, Physiological; Sulfonylurea Compounds; Testosterone; Treatment Outcome

2018
Simultaneous determination of metformin and glimepiride in human serum by ultra high performance liquid chromatography quadrupole time of flight mass spectrometry detection.
    Journal of pharmaceutical and biomedical analysis, 2019, Feb-20, Volume: 165

    Topics: Chromatography, High Pressure Liquid; Drug Monitoring; Female; Humans; Hypoglycemic Agents; Limit of Detection; Male; Metformin; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Sulfonylurea Compounds

2019
Applications of Fourier transform infrared spectroscopic method for simultaneous quantitation of some hypoglycemic drugs in their binary mixtures.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2019, Apr-15, Volume: 213

    Topics: Hypoglycemic Agents; Limit of Detection; Metformin; Pioglitazone; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Sulfonylurea Compounds; Vildagliptin

2019
Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes.
    Romanian journal of internal medicine = Revue roumaine de medecine interne, 2019, Sep-01, Volume: 57, Issue:3

    Topics: Actins; Ceruloplasmin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gene Expression; Humans; Hypoglycemic Agents; I-kappa B Proteins; Inflammation; Interleukin-2; Leukocytes, Mononuclear; Liraglutide; Male; Metformin; Middle Aged; NF-kappa B; Nod1 Signaling Adaptor Protein; Obesity; Pilot Projects; Prospective Studies; RNA, Messenger; Signal Transduction; Sirtuin 1; Sulfonylurea Compounds; Toll-Like Receptor 2; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha

2019
A Glimepiride-Metformin Multidrug Crystal: Synthesis, Crystal Structure Analysis, and Physicochemical Properties.
    Molecules (Basel, Switzerland), 2019, Oct-21, Volume: 24, Issue:20

    Topics: Chemistry, Pharmaceutical; Crystallography, X-Ray; Drug Combinations; Hypoglycemic Agents; Metformin; Solubility; Sulfonylurea Compounds; Wettability

2019
Adherence and Swallowing Experience with a Modified, Smaller-sized Tablet Formulation of Metformin and Glimepiride (SR) in Indian Patients with Type 2 Diabetes Mellitus.
    The Journal of the Association of Physicians of India, 2019, Volume: 67, Issue:12

    Topics: Blood Glucose; Deglutition; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Medication Adherence; Metformin; Sulfonylurea Compounds; Tablets

2019
Eff ectiveness of Teneligliptin as an Add-on in T2DM Patients not Controlled on Metformin and Glimepiride.
    The Journal of the Association of Physicians of India, 2020, Volume: 68, Issue:1

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrazoles; Sulfonylurea Compounds; Thiazolidines

2020
Multi-dimensional fingerprint profiling analysis for screening and quantification of illegal adulterated antidiabetics in hypoglycemic health products by aqueous two-phase extraction and multi-wavelength detection.
    Journal of chromatography. A, 2020, Jul-05, Volume: 1622

    Topics: Chromatography, High Pressure Liquid; Drug Contamination; Hypoglycemic Agents; Light; Limit of Detection; Metformin; Reproducibility of Results; Spectrum Analysis; Sulfonylurea Compounds

2020
Clinical Utilization Pattern of Multiple Strengths of Glimepiride and Metformin Fixed Dose Combinations in Indian Type 2 Diabetes Patients.
    The Journal of the Association of Physicians of India, 2020, Volume: 68, Issue:7

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Metformin; Sulfonylurea Compounds

2020
Oral anti-diabetic drugs as endocrine disruptors in vitro - No evidence for additive effects in binary mixtures.
    Toxicology in vitro : an international journal published in association with BIBRA, 2021, Volume: 70

    Topics: Administration, Oral; Cell Line; Chromatography, Liquid; Drug Interactions; Endocrine Disruptors; Humans; Hypoglycemic Agents; Metformin; Simvastatin; Sitagliptin Phosphate; Steroids; Sulfonylurea Compounds; Tandem Mass Spectrometry

2021
Increased osteoprotegerin level is associated with impaired cardiovagal modulation in type-2 diabetic patients treated with oral antidiabetic drugs.
    BMC cardiovascular disorders, 2020, 10-20, Volume: 20, Issue:1

    Topics: Administration, Oral; Adult; Biomarkers; Cardiometabolic Risk Factors; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Heart; Humans; Hypoglycemic Agents; India; Male; Metformin; Middle Aged; Osteoprotegerin; Risk Assessment; Sulfonylurea Compounds; Treatment Outcome; Up-Regulation; Vagus Nerve

2020
[Starting insulin or not? And if so, which basal insulin?]
    Nederlands tijdschrift voor geneeskunde, 2020, 09-24, Volume: 164

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Insulins; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Weight Loss

2020
Sensitive detection of antidiabetic compounds and one degradation product in wastewater samples by a new SPE-LC-MS/MS method.
    Journal of environmental science and health. Part A, Toxic/hazardous substances & environmental engineering, 2021, Volume: 56, Issue:3

    Topics: Chromatography, Liquid; Environmental Monitoring; Gliclazide; Glipizide; Glyburide; Hypoglycemic Agents; Metformin; Reproducibility of Results; Solid Phase Extraction; Sulfonylurea Compounds; Tandem Mass Spectrometry; Wastewater; Water Pollutants, Chemical

2021
Impacts of early insulin treatment vs glimepiride in diabetic patients with background metformin therapy: A nationwide retrospective cohort study.
    Medicine, 2021, Mar-05, Volume: 100, Issue:9

    Topics: Adult; Aged; Cause of Death; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Population Surveillance; Retrospective Studies; Sulfonylurea Compounds; Taiwan; Time Factors; Treatment Outcome

2021
Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia.
    Clinical pharmacology and therapeutics, 2022, Volume: 111, Issue:1

    Topics: Administrative Claims, Healthcare; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Carbamates; Databases, Factual; Diabetes Mellitus, Type 2; Drug Interactions; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Medicaid; Metformin; Middle Aged; Nateglinide; Pharmacoepidemiology; Piperidines; Secretagogues; Sulfonylurea Compounds; United States

2022
Emulating the GRADE trial using real world data: retrospective comparative effectiveness study.
    BMJ (Clinical research ed.), 2022, 10-03, Volume: 379

    Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome

2022
Effect of Dietary Fiber on the Level of Free Hypoglycemic Agents in Vitro.
    Biological & pharmaceutical bulletin, 2022, Volume: 45, Issue:11

    Topics: Buformin; Dietary Fiber; Hypoglycemic Agents; Metformin

2022
Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study.
    Indian journal of public health, 2022, Volume: 66, Issue:Supplement

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; India; Metformin; Prospective Studies; Quality of Life

2022
[In patients with type 2 diabetes on metformin, the addition of which antihyperglycemic class among a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 agonist (liraglutide), or basal insulin (glargine) is the most effective to achieve
    La Revue de medecine interne, 2023, Volume: 44, Issue:1

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycemic Control; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Liraglutide; Metformin; Sitagliptin Phosphate; Treatment Outcome

2023
In type 2 diabetes, glargine and liraglutide each improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin.
    Annals of internal medicine, 2023, Volume: 176, Issue:1

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Sitagliptin Phosphate; Treatment Outcome

2023
Analytical Method Capable of Quantifying Eight Nitrosamine Impurities from Five Different Commercially Available Metformin Formulations with Glipizide, Glibenclamide, Gliclazide, Evogliptin, and Glimepiride by Ultra High Performance Liquid Chromatography
    Journal of pharmaceutical sciences, 2023, Volume: 112, Issue:5

    Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Diabetes Mellitus, Type 2; Gliclazide; Glipizide; Glyburide; Humans; Metformin; Nitrosamines; Pharmaceutical Preparations; Tandem Mass Spectrometry

2023
Assessment of empagliflozin add-on therapy to metformin and glimepiride in patients with inadequately controlled type-2 diabetes mellitus.
    Pakistan journal of pharmaceutical sciences, 2022, Volume: 35, Issue:6(Special)

    Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Follow-Up Studies; Glycated Hemoglobin; Humans; Metformin

2022
Deduction of the operable design space of RP-HPLC technique for the simultaneous estimation of metformin, pioglitazone, and glimepiride.
    Scientific reports, 2023, 03-16, Volume: 13, Issue:1

    Topics: Chromatography, High Pressure Liquid; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Thiazolidinediones

2023
COMPARATIVE EFFECT OF INSULIN, GLIMEPIRIDE, AND METFORMIN ON INFLAMMATORY MARKERS IN TYPE 2 DIABETES MELLITUS.
    Georgian medical news, 2023, Issue:335

    Topics: Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Insulin; Metformin

2023